Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016